Erste Group Upgrades Eli Lilly (LLY) to Buy Following Strong First-Half Results

Core Insights - Eli Lilly and Company (NYSE: LLY) has been upgraded to a "Buy" rating by Erste Group following strong first-half results and an optimistic outlook for 2025 [3][4] - The company expects annual revenue between $60 billion and $62 billion, with earnings per share projected between $21.80 and $23.00 [4] - Eli Lilly has a strong track record of dividend payments, having raised its dividend for 11 consecutive years, with a current quarterly dividend of $1.50 per share and a yield of 0.74% [5] Financial Performance - Eli Lilly's stock has increased by over 4% since the beginning of 2025, reflecting positive market sentiment [2] - The company has revised its full-year 2025 outlook for both revenue and earnings per share upwards after reporting impressive mid-year results [3][4] Market Position - Erste Group anticipates that Eli Lilly will continue to gain market share within the pharmaceutical industry, despite potential impacts from recently announced tariffs being limited and already reflected in the updated guidance [4]